)
)
Edge16 Oct 2026
Winner, Winner: The Chicken McNugget Story
How a 1940s breeding contest, a Cornell food scientist, and a hedge by Ray Dalio helped McDonald's turn the Chicken McNugget into a fast-food icon.
Inari Medical
Inari Medical (NARI) investor relations material
Inari Medical has been acquired by Stryker Corporation
Inari Medical Jefferies London Healthcare Conference 2024 summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Jefferies London Healthcare Conference 2024 summary20 Nov, 2024
Strategic overview and growth drivers
Focused on venous thromboembolism (VTE) with two purpose-built platforms for PE and DVT, treating over 165,000 patients since 2016.
Expanding into four adjacent markets with unmet needs, leveraging similar purpose-built tools.
International expansion underway, now in 15+ markets across Latin America and Asia-Pacific, with growing contributions.
U.S. VTE market development and penetration
U.S. VTE market has a $6B TAM with 700,000 annual cases; only 8% currently treated with company’s platforms.
Majority of patients still managed conservatively; early stages of shifting to catheter-based interventions.
Long-term vision is to reach penetration rates similar to STEMI (90%+), moving away from lytic-based therapies.
Clinical evidence and impact
PEERLESS RCT showed FlowTriever superior to catheter-directed thrombolysis (CDT) in intermediate-risk PE, with immediate patient improvement and shorter hospital stays.
60% lower 30-day readmission rate for FlowTriever vs. CDT; potential $150M revenue opportunity from share shift.
Strong physician feedback and RCT-level evidence expected to accelerate adoption.
Ongoing trials: PEERLESS II (FlowTriever vs. anticoagulation), PERSEVERE (high-risk PE), and DEFIANCE (DVT).
Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.Research faster. Power your platform.
Latest events from Inari Medical
- Q3 2024 revenue up 21.4% to $153.4M, net loss $18.4M, guidance raised for 2024.NARI
Q3 2024 - Strong safety, robust clinical trials, and new launches drive growth and global expansion.NARI2024 Wells Fargo Healthcare Conference
- Q2 growth and market leadership set the stage for accelerated expansion and profitability in 2025.NARIMorgan Stanley 22nd Annual Global Healthcare Conference
- Q2 2024 revenue up 23% year-over-year, but net loss widened to $31.3 million.NARIQ2 2024
Inari Medical
AI chat
Ask anything. Verify everything.
Ask across every event and document from public companies. Each answer links back to the exact line in the transcript, slide or filing it came from.Learn moreFind what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.)
Trust every finding
50m+ first-party documents. Every output traceable to its source.Find what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.Trust every finding
50m+ first-party documents. Every output traceable to its source.Automations
Zero in on what matters
Define the prompt once. It runs the moment a company publishes or on a schedule you set. Outputs map to the exact signals you choose.Learn more)
Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.)
Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Live audio & transcripts
Be first
Join any earnings call live in one click, with no manual registration. Follow the transcript as it happens and jump straight to the moments that matter.Learn more)
Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.)
Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Quartr MCP connects your AI environment to 17K+ public companies
Pull live transcripts, filings, and slides into Claude or Codex via MCP. Combine Quartr's global IR data with any other dataset. Run agentic research and monitoring.
Included with Quartr Pro at no extra cost.Learn more
Quartr's AI stands out because it only pulls clean, first-party data from public companies. In investing, that's everything.
Jamie Ross
Investment Manager, GAM Investments
GAM
GAM
Research that used to take hours now takes seconds with Quartr Pro. Tracking shifts in tone or extracting tables, it's as simple as typing a query.
Tom O'Hara
Investment Director
Ciena
Ciena
Before Quartr we spent hours manually compiling insights through the peer earnings cycle. Now, these tasks are done faster, with greater precision.
Gregg Lampf
VP of Investor Relations
Protean
Protean
Being able to ask specific questions across years of transcripts and reports and instantly get verified answers is a game-changer.
Pontus Dackmo
CEO & Investment Manager
)
)
Frequently asked questions
Inari Medical, Inc. develops, manufactures, markets, and sells its own line of devices for the interventional treatment of deep vein thrombosis, other arterial and venous diseases and cancerous lesions in the United States. The medical devices are inserted into the body either through an opening in the skin or a regionally accessed blood vessel or structure. Inari Medical, Inc. was incorporated in 2011 and is headquartered in Irvine, California.